Vesper Healthcare Acquisition Corp.
Completed 2021-05-04- CIK 1818093
- VSPR
- Now SKIN
- IPO 2020-09-30
- 436 filings
Successfully merged with The HydraFacial Company • Now trading as SKIN
- IPO Size
- $460M
- raised at the IPO
- Current Status
- Completed
- from its latest filing
- IPO Year
- 2020
- year it listed
Filings, by quarter
436 filings over 26 quarters; violet bars carry a milestone
- 20 Q3: 13 filings
- 20 Q4: 9 filings
- 21 Q1: 15 filings
- 21 Q2: 46 filings
- 21 Q3: 38 filings
- 21 Q4: 13 filings
- 22 Q1: 24 filings
- 22 Q2: 28 filings
- 22 Q3: 16 filings
- 22 Q4: 19 filings
- 23 Q1: 14 filings
- 23 Q2: 22 filings
- 23 Q3: 20 filings
- 23 Q4: 13 filings
- 24 Q1: 10 filings
- 24 Q2: 16 filings
- 24 Q3: 12 filings
- 24 Q4: 14 filings
- 25 Q1: 11 filings
- 25 Q2: 18 filings
- 25 Q3: 10 filings
- 25 Q4: 10 filings
- 26 Q1: 12 filings
- 26 Q2: 19 filings
- 26 Q3: 13 filings
- 26 Q4: 1 filing
- S-1 filed 20 Q3
- IPO 20 Q3
- Definitive agreement 20 Q4
- Completed 21 Q2
SPAC Overview
Where it stands on the road from S-1 to merger
Timeline Progress
About
Vesper Healthcare Acquisition Corp. is a blank check company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It intends to focus on pharmaceuticals and healthcare, especially medical aesthetics, eye care, longevity and wellness.
Investment Focus
Biopharmaceuticals, Healthcare
Key Information
As the filings state it
- IPO Date
- 2020-09-30
- PIPE
- $350M
- Jurisdiction of Incorporation
- Delaware
- SIC
- 6770
- Completion Date
- 2021-05-04
- Merger Target
- The HydraFacial Company
- SPAC Ticker
- VSPR
- Merged Ticker
- SKIN
Stock Performance
SKINTrading symbol, and its price at each step since the first trade
| Point | Date | Price | Move |
|---|---|---|---|
| First Trade | 2020-11-24 | $10.84 | |
| At Merger | 2021-05-05 | $12.49 | +15% |
| 6 Months Post-Merger | 2021-11-04 | $29.33 | +135% |
| 1 Year Post-Merger | 2022-05-05 | $12.94 | +4% |
| 2 Years Post-Merger | 2023-05-05 | $10.49 | -16% |
| Current Price | 2026-10-09 | $0.55 | -95% |
SPAC Team
The banks on its IPO, and the team as the filings describe it
Underwriters
Extended Team Information
Led by Brenton L. Saunders and Manisha Narasimhan, whose experience includes leadership roles in pharmaceutical, biotechnology and aesthetics companies. The team also includes nominees Michael D. Capellas, Julius Few and Barry S. Sternlicht, with experience across technology, healthcare/aesthetics, and real estate and investment management.